提前2個月交付！瑞士山谷中，他們再次成功挑戰(zhàn)“不可能” | 逐夢者說 | Bilingual

編者按：“讓天下沒有難做的藥，難治的病”，是初心，更是愿景。自成立以來，藥明康德步履不停：從一間實(shí)驗(yàn)室，到覆蓋亞洲、歐洲和北美的全球網(wǎng)絡(luò)。從早期的化學(xué)合成服務(wù)，到貫穿研究（R）、開發(fā)（D）和生產(chǎn)（M）的一體化平臺。從第一位客戶，到全球三十多個國家的數(shù)千合作伙伴。不斷發(fā)展的，是規(guī)模與能力；始終堅(jiān)守的，是夢想與承諾。

致敬來時路，共譜新篇章！在這一系列訪談中，我們以“逐夢者”視角，回顧藥明康德成長發(fā)展的崢嶸歲月，回望賦能客戶創(chuàng)新的并肩往事，更以獨(dú)特的“藥明精神”展望未來新篇章。

十月的瑞士陽光清朗，清晨的汝拉山被一層薄霧輕柔籠罩，山林間偶爾傳來幾聲清脆的鳥鳴。在這片靜謐的山谷中，藥明康德庫威（Couvet）基地也漸漸蘇醒。

就在這份寧靜中，基地負(fù)責(zé)人杰米·安德魯斯（Jamie Andrews）接收到一封特別的郵件。發(fā)送郵件的是一位正在合作的客戶，他希望將一批關(guān)鍵臨床藥物的交付時間提前整整一個月。

留給團(tuán)隊(duì)的時間被驟然壓縮了一半。

一場跨時區(qū)的項(xiàng)目會議迅速召開。來自歐洲與中國的研發(fā)、生產(chǎn)、質(zhì)量、分析等團(tuán)隊(duì)在線聚集。杰米在會議中語速平穩(wěn)卻堅(jiān)定地傳達(dá)了客戶的新需求，同時迅速制訂了新的時間表——在寧靜的汝拉山山谷里，一場與時間賽跑的競賽悄然開啟。

盡管時間縮短，一切流程卻依然有條不紊地展開。在杰米看來，這份從容源自藥明康德全球一體化CRDMO平臺的自信與底氣。

對他而言，這份沉著應(yīng)對早已成為一種經(jīng)過歲月打磨的本能——一種根植于他多年制藥生涯的肌肉記憶。

從汝拉山到地球村：繪制全球化網(wǎng)絡(luò)

杰米的職業(yè)旅程足跡遍布全球。26年前，他在澳大利亞一家公司擔(dān)任工程師，此后投身醫(yī)藥行業(yè)。隨后，他先后輾轉(zhuǎn)英國和愛爾蘭，直到2010年定居瑞士。

2021年，杰米加入藥明康德瑞士庫威基地，為自己的全球化旅程增添了嶄新一筆。

在庫威，杰米的全球背景以及國際視角，與藥明康德的全球化使命相得益彰。

從一間650平方米的實(shí)驗(yàn)室起步，經(jīng)過多年的發(fā)展，藥明康德在亞洲、歐洲和北美擁有二十多個研發(fā)和生產(chǎn)基地。從中國到新加坡，從瑞士到美國，藥明康德的CRDMO業(yè)務(wù)平臺如同一張精準(zhǔn)編織的“分子地圖”，在不同經(jīng)緯線間協(xié)同運(yùn)轉(zhuǎn)。

其中，坐落在歐洲創(chuàng)新高地的庫威基地，在藥明康德全球CRDMO賦能平臺中扮演著重要角色。立足于當(dāng)?shù)?，這個專注于制劑商業(yè)化生產(chǎn)和包裝的基地，正為全球多地的客戶提供賦能。

如今，藥明康德庫威基地正在為歐洲、美國、加拿大、日本、澳大利亞和新西蘭的客戶提供支持，并于近期獲得GMP認(rèn)證，進(jìn)一步打開巴西和土耳其等新興市場的大門。

完成“不可能的任務(wù)”

談及全球化合作時，杰米回想起一次印象深刻的經(jīng)歷。

當(dāng)時，杰米收到了一位客戶的請求，對方期望盡快啟動一個商業(yè)化項(xiàng)目。令客戶頭疼的是，某些原料在當(dāng)?shù)氐牟少徶芷诼L，按時啟動項(xiàng)目幾乎是一項(xiàng)不可能完成的任務(wù)。

當(dāng)客戶抱著試試看的心態(tài)發(fā)來郵件時，杰米卻顯得從容不迫：“憑借藥明康德全球運(yùn)營網(wǎng)絡(luò)的優(yōu)勢，及時成功采購所有原料并非不可能?！?/p>

在團(tuán)隊(duì)協(xié)調(diào)下，項(xiàng)目所需原料很快完成采購并運(yùn)抵庫威。依托藥明康德的全球網(wǎng)絡(luò)，庫威基地提前完成了客戶“不可能的挑戰(zhàn)”，保證了項(xiàng)目的及時啟動。

這樣的故事，在杰米的記憶中屢見不鮮。

在另一次合作中，得益于與藥明康德在上海外高橋和無錫的團(tuán)隊(duì)緊密合作，庫威基地快速完成技術(shù)轉(zhuǎn)移及生產(chǎn)等，助力客戶順利遞交了新藥申請（NDA）。這些跨區(qū)域團(tuán)隊(duì)間無縫銜接的合作經(jīng)歷，也讓杰米在應(yīng)對各類客戶需求的時候更加信心十足。

在杰米看來，這些高效運(yùn)轉(zhuǎn)的全球協(xié)作，離不開藥明康德全球一體化CRDMO模式的支持。而其中的核心理念正是“跟隨科學(xué)、跟隨客戶、跟隨分子”。

這一理念意味著，基于獨(dú)特的一體化CRDMO平臺，藥明康德能夠從分子發(fā)現(xiàn)之初，陪伴客戶一路走到藥物上市的終點(diǎn)。

例如，一個項(xiàng)目在藥明康德的其他基地完成了早期臨床階段開發(fā)后，可以無縫銜接到庫威基地，將項(xiàng)目推進(jìn)到后期臨床和商業(yè)化生產(chǎn)階段。這種全周期、一體化的支持，能避免多環(huán)節(jié)轉(zhuǎn)移帶來的時間延誤與技術(shù)風(fēng)險。

客戶對庫威基地的信任，同樣離不開藥明康德25年來長期堅(jiān)守的全球質(zhì)量體系。

2009年以來，藥明康德化學(xué)業(yè)務(wù)平臺成功通過全球監(jiān)管機(jī)構(gòu)的審計(jì)超過140次，所支持的創(chuàng)新藥在全球超過100個國家和地區(qū)上市。得益于出色的質(zhì)量記錄，已有25次新藥上市批準(zhǔn)前檢查（PAI，Pre-Approval Inspection）得到美國FDA和EMA豁免。

在藥明康德庫威基地，全球統(tǒng)一的質(zhì)量標(biāo)準(zhǔn)體系確保了結(jié)果的一致性。在這里生產(chǎn)的產(chǎn)品經(jīng)過包裝，可發(fā)往歐洲、北美或亞太的不同地區(qū)。

面向未來，持續(xù)建設(shè)新能力

在藥明康德的4年間，杰米親歷了庫威基地產(chǎn)能與能力的持續(xù)提升。例如，為了滿足持續(xù)增長的客戶需求，庫威基地新增了干法制粒、濕法制粒和OEB4高密閉設(shè)備等全新的口服固體制劑技術(shù)。

“在2024年，我們已經(jīng)實(shí)現(xiàn)了口服制劑產(chǎn)能的翻倍?！苯苊捉榻B道，2025年，庫威基地每年可生產(chǎn)多達(dá)20億片藥片和2.5億粒膠囊，包裝方面可支持1.5億個泡罩和1500萬瓶藥瓶。

庫威基地產(chǎn)能與能力拓展的步伐仍在延續(xù)。這一切，正是“為未來而建”。

在2025年9月，杰米見證著基地中一座五層新樓的封頂。這是庫威基地全新的制劑大樓，配備了噴霧干燥設(shè)備（PSD-4），預(yù)計(jì)將于2026年四季度投入運(yùn)營，為全球客戶提供噴霧干燥能力——一項(xiàng)提升小分子口服吸收能力的關(guān)鍵技術(shù)。

未來，庫威基地還將進(jìn)一步拓展賦能平臺，包括引入注射劑生產(chǎn)線和脂質(zhì)納米粒技術(shù)，來滿足客戶多樣化需求。

在挑戰(zhàn)中前行

結(jié)束會議后，杰米捧起尚有余溫的咖啡，望向窗外。周圍風(fēng)景依舊，汝拉山麓綠草如茵，山林間依舊有鳥兒掠過，一切又回歸到了開始的寧靜。

正如眼前的景象所映照的那樣，在全球化賦能創(chuàng)新的過程中，藥明康德堅(jiān)定地承擔(dān)著企業(yè)社會責(zé)任，踐行可持續(xù)發(fā)展理念。

在庫威基地，屋頂?shù)奶柲茈姵匕迕磕昴芴峁?75兆瓦時的能源，足以為一部手機(jī)每天充電，長達(dá)5萬年。同時，這里的所有廢水均經(jīng)過特殊處理，將對環(huán)境產(chǎn)生的影響降到極低；實(shí)驗(yàn)室的印刷材料，也通過專業(yè)回收，進(jìn)入下一個生命循環(huán)……

這些努力也得到了國際權(quán)威評級機(jī)構(gòu)的認(rèn)可。2024年11月，庫威基地獲得全球企業(yè)社會責(zé)任評級專業(yè)機(jī)構(gòu)EcoVadis銀牌認(rèn)證，在所有參與評級的公司中排名前9%。

無論是在瑞士庫威，還是全球其他基地，可持續(xù)發(fā)展理念始終貫穿了藥明康德的戰(zhàn)略與運(yùn)營。

回到電腦前，杰米又投入到下一位客戶的項(xiàng)目中。對他來說，這次挑戰(zhàn)是作為庫威基地負(fù)責(zé)人日常工作的一個縮影。在藥明康德，挑戰(zhàn)并不罕見。它們更像是一場場新的冒險，帶來新的經(jīng)歷和突破。

偶爾，杰米也會回想過去的工作。那時，他的整個職業(yè)生涯或許只會追隨一兩個分子的研發(fā)到市場化工作。而如今，他的日常是每天都在努力幫助客戶將各種分子的開發(fā)加速推進(jìn)，為患者帶來更多創(chuàng)新藥物。

“這是我真正的動力，早日實(shí)現(xiàn)‘讓天下沒有難做的藥，難治的病’的偉大愿景?！苯苊渍f。

At Couvet, Speed has an Address

Editor’s Note: “Every drug can be made and every disease can be treated”. Since 2000, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to thousands of partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision.

In tribute to the journey, we look back through the eyes of our “dream-makers”: revisiting the stories of partnership that empowered global innovation, and the unique spirit that continues to guide us toward the next chapter.

On a crisp, sunny October morning in Couvet, Switzerland, a request comes into Jamie Andrews’ phone: a client needs a critical clinical batch one month earlier than scheduled; the new deadline is in just four weeks.

Within hours, Andrews has quality, analytical, and project teams in Europe and China moving in parallel. As one team drafts protocols, another pulls testing windows forward and untangles the supply paths.

“There’s always a way to get things done,” Andrews says. For the head of WuXi AppTec’s Couvet site, that steady composure is built from a career of hopping hemispheres and stitching together production lines that span continents.

A Global Life, a Global Mandate

Andrews began his career in Australia, trained as an engineer. More than 20 years in pharma took him from Australia to England, Ireland, and finally Switzerland in 2010. He joined WuXi AppTec in 2021, bringing a distinctly international lens, borne from a career spent reading problems from multiple time zones at once.

His global background matters because Couvet’s daily work is international by design. Set in the center of Europe, the site supports clients across Europe, the U.S., Canada, Japan, Australia, New Zealand, and beyond, and has recently added GMP certifications that open doors in markets such as Brazil and Turkey. It is the hub for manufacturing, packaging, and testing late-stage clinical and commercial oral solid drug products, plugged directly into WuXi AppTec’s “follow the molecule” network from discovery to launch. “We enhance supply chain flexibility for our clients, providing a cost-effective option to deliver high-quality drug products to patients worldwide,” Andrews says.

Behind that reach are capacity and capability. “There’s already been significant investment at our site,” Andrews says. In recent years, the site has installed new oral-solid-dosage technologies such as dry granulation, wet granulation, and OEB4 high-containment equipment to support a broader range of client needs.

“Additionally, we have doubled manufacturing and packaging capacities,” he continues. In 2025, the lines can turn out up to 2 billion tablets and 250 million capsules a year, and package 150 million blister packs, plus 15 million bottles annually.

A Global CRDMO for Global Customers

Couvet’s advantage lies in how it operates within WuXi AppTec’s global CRDMO system (Contract Research, Development, and Manufacturing Organization). “Our customers like to work with one company,” Andrews says. “Often, after partnering with other WuXi AppTec teams in early clinical stages, they are ready to commercialize, and that is where our site comes in.” By completing journeys that begin at sister sites around the world, Couvet delivers products through global synergy and a seamless handover.

Andrews points to two moments that show how the network supports clients in complex projects. In one program, a client was preparing a commercial launch of a complex product, and sourcing key materials on time was challenging. Few vendors could deliver within the window.

“By leveraging the strength of our global network, we were able to successfully secure all the materials and keep the project on track.” Andrews said. A team in Shanghai secured the materials quickly, while a project management team streamlined activities in parallel, so no step idled in the middle.

With the support, the Couvet site delivered the results ahead of expectation. “That allowed us to meet the client’s launch schedule and most importantly, deliver the drug products to patients without delay.” Andrews says.

In another example, teams across Shanghai, Wuxi City, and Couvet collaborated closely, quickly aligned the manufacturing process and completed an NDA submission successfully.

According to Andrews, this is why customers increasingly seek partners with a true global footprint, not just a single manufacturing location but multiple qualified sites around the world, so that supply is resilient and secure.

Global Spirit, Locally Established

Serving globally is easier said than done. At Couvet, a single bulk batch can be packaged and released for Europe, North America, or Asia Pacific. A harmonized global quality system keeps outcomes consistent. “We have the same policies, the same procedures, the same document management systems across all our sites to ensure we produce the same high level of quality,” Andrews said, “and, most importantly, to protect patient safety.”

To Andrews, however, global reach does not mean losing sight of local roots. Originally a commercial manufacturing site within a large pharmaceutical company, the Couvet site built a strong quality track record with European authorities and the FDA, and it has maintained excellence in commercial manufacturing.

From Andrews’s window, the Jura Mountains roll away into green grass and forest. Environmental stewardship matters in Switzerland, and it shows in his team’s operations. The site integrates sustainability into daily practice, generating 175 MWh of renewable energy annually from rooftop solar panels, enough to charge a mobile phone every day for 50,000 years. Alongside wastewater treatment and materials recycling, the site earned a Silver EcoVadis medal, placing it in the top 9% of rated companies.

It also stays close to its community, from engaging local suppliers on expansion projects to turning the company Christmas party into a small marketplace where regional artisans and producers were invited to sell their goods. “We are part of an ecosystem here,” Andrews says. “We try to contribute to it.”

Building for What’s Next

The next chapter at Couvet is already framed in scaffolding. Just beyond the packaging halls, crews are installing a commercial PSD-4 spray-drying suite built for the kind of tricky, low-solubility compounds that clients increasingly ask for. The structure is slated to be operational in Q4 2026. Looking further ahead: Andrews’ team is laying the groundwork for parenteral drug-product capabilities, including injectable manufacturing lines and lipid-nanoparticle technologies, so a client can move from tablets and capsules to sterile formats without leaving the WuXi AppTec global enabling platform.

Scale is another multiplier. Having doubled manufacturing and packaging capacity, Couvet can absorb programs with heavier volume profiles and give clients room to ramp a launch, to ride demand spikes, to consolidate supply under one roof.

“One of the things I really appreciate about working at WuXi AppTec is the challenge that comes every day. It's like being on an adventure. I am doing different things every day.” Andrews says. “That's my day-to-day job, bringing innovative products to patients. That's what really motivates me.”

免責(zé)聲明：本文 僅作信息交流之目的，文中觀點(diǎn)不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點(diǎn)。本文也不是治療方案推薦。如需獲得治療 方案指導(dǎo)，請前往正規(guī)醫(yī)院就診。

版權(quán)說明：歡迎個人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺。轉(zhuǎn)載授權(quán)請?jiān)凇杆幟骺档隆刮⑿殴娞柣貜?fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。